EICHORCondition: Metastatic Castration-Resistant Prostate Cancer · Sponsor: Zenith Epigenetics
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC who have progressed on prior abiraterone by PCWG3 criteria. Disease must have progressed on only abiraterone by PCWG3 criteria prior to study entry. The patient population will be separated into two cohorts: Cohort A: Patients with poor response to prior abiraterone defined as: * Abiraterone started in hormone-sensitive prostate cancer (HSPC) disease setting: \< 12 months duration on abiraterone or failure to achieve PSA nadir of 0.2 ng/mL while taking abiraterone, or; * Abiraterone started in castrate-resistant prostate cancer (CRPC) disease setting: \< 6 months duration on abiraterone or failure to achieve PSA50 response while on abiraterone Cohort B: Patients with response to prior abiraterone, defined as: * Abiraterone started in hormone-sensitive prostate cancer (HSPC) disease setting: ≥ 12 months duration on abiraterone and nadir PSA \< 0.2 ng/mL, or; * Abiraterone started in castrate-resistant prostate cancer (CRPC) disease setting: ≥ 6 months duration on abiraterone and confirmed PSA50 response
This description comes directly from the study's public registry record.
Zenith Study Team · 587-390-7865 · ZEN003694-201@zenithepigenetics.com
Always discuss trial participation with your own doctor first.
| California Research Institute | Los Angeles, California, United States | Recruiting |
| University of California, San Francisco | San Francisco, California, United States | Recruiting |
| Innovative Clinical Research Institute | Whittier, California, United States | Recruiting |
| Colorado Urology | Lakewood, Colorado, United States | Recruiting |
| D&H Cancer Research Center, LLC | Margate, Florida, United States | Recruiting |
| BRCR Global | Plantation, Florida, United States | Recruiting |
| Hematology Oncology Clinic | Baton Rouge, Louisiana, United States | Withdrawn |
| Maryland Oncology Hematology, P.A. | Columbia, Maryland, United States | Recruiting |
| University of Michigan Rogel Cancer Center | Ann Arbor, Michigan, United States | Recruiting |
| Weill Cornell Medical College - New York Presbyterian Hospital | New York, New York, United States | Completed |
| Messino Cancer Center | Asheville, North Carolina, United States | Recruiting |
| Northwest Cancer Specialists, P.C. | Portland, Oregon, United States | Recruiting |
+ 19 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04986423